Scalper1 News
Specialty drugmaker Horizon Pharma jumped more than 3% to a new high Monday after it issued strong preliminary Q2 sales and raised its full-year guidance. Horizon (HZNP) said sales in the quarter were about $170 million to $172 million, roughly a 160% increase over the year-earlier quarter and more than $40 million above analysts’ consensus, according to Thomson Reuters. It didn’t release any earnings numbers, but said Q2 EBITDA margin should be Scalper1 News
Scalper1 News